Pharmacological Management of Portal Hypertension in Liver Cirrhosis

Portal hypertension arises from increased intrahepatic vascular resistance and a hyperdynamic circulatory state in cirrhosis, driving complications such as variceal bleeding, ascites and hepatic encephalopathy. Pharmacological management centres on reducing portal pressure and mitigating these risks. First-line therapy consists of non-selective beta-blockers that lower cardiac output and induce splanchnic vasoconstriction. Carvedilol, with additional α₁-adrenergic blockade, achieves more potent haemodynamic reduction but requires careful dose uptitration to avoid systemic hypotension and renal dysfunction. Biomarkers such as von Willebrand factor now inform non-haemodynamic benefits, notably anti-inflammatory effects. Hepatic venous pressure gradient (HVPG) measurement remains the gold standard for assessing treatment response, while non-invasive surrogates are under development to personalise care. Adjunctive agents—including statins, anticoagulants and vasoactive peptides—target endothelial dysfunction and fibrogenesis, broadening therapeutic options. Integrating these strategies aims to prevent decompensation, reduce mortality and improve transplant-free survival in diverse patient populations worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Management of Portal Hypertension in Liver Cirrhosis publication trend

The graph below shows the total number of articles in pharmacological management of portal hypertension in liver cirrhosis across all publications each year (not limited to Nature Index journals).

Technical terms

Portal hypertension: Elevated pressure within the portal venous system due to increased hepatic vascular resistance and hyperdynamic circulation in cirrhosis.

Non-selective beta-blocker (NSBB): A class of agents blocking β₁ and β₂ receptors, reducing cardiac output and inducing splanchnic vasoconstriction to lower portal pressure.

Carvedilol: A non-selective beta-blocker with additional α₁-adrenergic blockade, providing more potent reduction of portal pressure but with increased risk of systemic hypotension.

Hepatic venous pressure gradient (HVPG): The invasive gold-standard measurement of portal pressure, guiding therapeutic efficacy and prognostic assessment.

Von Willebrand factor (VWF): An endothelial biomarker reflecting systemic inflammation and vascular dysfunction, used to gauge non-haemodynamic responses to therapy.

References

1. Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring?. Current Hepatology Reports (2019).
2. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clinical Gastroenterology and Hepatology (2021).
3. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. Clinical Gastroenterology and Hepatology (2022).
4. Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers A Tailored Approach. Clinics in Liver Disease (2021).
5. The Role of Anticoagulation in Treating Portal Hypertension. Current Hepatology Reports (2018).
6. Severe carvedilol toxicity without overdose – caution in cirrhosis. Clinical Hypertension (2017).
7. Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?. Frontiers in Medicine (2023).